JPMorgan sees 2026 as ‘pivotal year’ for Zimmer Biomet

JPMorgan thinks 2026 is set up to be a “pivotal year” for Zimmer Biomet (ZBH). The analyst keeps a Neutral rating on the shares with a $100 price target Investors want Zimmer to “deliver a boring, consistent, beat and raise year” where results outperform expectations, the analyst tells investors in a research note. After meeting with management, JPMorgan thinks the company’s fundamentals are in “good shape, with portfolio gaps filled and plenty of opportunities for growth.” It views Zimmer’s 2026 as conservative and sees potential for a year for the stock.